加利福尼亚州尔湾 - 市值达18.2亿美元的眼科护理和传染病预防专业公司Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)今日宣布启动1亿美元普通股的公开发行。根据InvestingPro数据显示，该公司财务状况稳健，流动比率为4.42，现金储备超过债务。该公司因其获FDA批准的睑缘蠕形螨睑炎治疗药物XDEMVY（0.25%洛替拉尼眼用溶液）而闻名，并将给予承销商 ...

Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...

U.S. Customs and Border Protection (CBP) has claimed an object that people from Quinlan say fell from the sky on Tuesday ...

Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $58 from $54 and keeps a Buy rating on the shares. The firm says ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

Tarsus Pharmaceuticals Inc (TARS) reports robust sales and strategic advancements, despite high operating expenses and market challenges.

However, according to the Commonwealth Ombudsman, designated communications providers (DCPs) are receiving duplicated ...